Lifeline Scientific, Inc New business wins in the US and Brazil (2832I)
08 Dezember 2015 - 8:00AM
UK Regulatory
TIDMLSIC
RNS Number : 2832I
Lifeline Scientific, Inc
08 December 2015
Lifeline Scientific, Inc.
("Lifeline" or the "Company")
Significant New Business in North America and Brazil
Lifeline Scientific (AIM: LSIC), the transplantation technology
company, announces significant new business wins in North America
and Brazil, which combined are expected to contribute in excess of
US$1.5m in annualised revenues.
Key account wins in the US
Lifeline has continued to grow its key North American customer
base with orders for LifePort Kidney Transporters, related
consumables and preservation solutions from several new US regions.
New and expanded business includes key accounts in the organ
procurement regions of Southern California, Kentucky, Nebraska and
northern Florida. Total revenue from this new business is
anticipated to exceed US$0.8m during the next 12 months. These
programmes combined are estimated to recover more than 700 kidneys
for transplant annually. LifePort Kidney Transporter is the
standard of care for machine preservation of donor kidneys in most
donor organ procurement programmes within the US and in all
provinces of Canada. North America remains the largest
contributor to the Company's revenue base, accounting for nearly
79% of total transplantation and services revenues in the year
ended 31 December 2014.
Significant Orders and New Clinical Evidence from Brazil
In addition, the Company announces a significant order of
LifePort Kidney Transporter consumables and preservation solutions
from the State of Rio de Janeiro and a new LifePort site in the
state of Goias, in Central Brazil. These orders total approximately
US$0.78m and come on the back of significant new clinical evidence
supporting LifePort adoption that was presented at last month's
annual meeting of the Brazilian Society of Transplantation.
Separate presentations from four major transplant programmes each
demonstrated important clinical and economic benefits for LifePort
vs. Brazil's present standard of donor kidney preservation, static
cold storage (a cool box filled with ice). Among the data presented
were outcomes of Brazil's pivotal 120 patient independent
investigator driven multi-centre (10 centres), randomised,
prospective, controlled LifePort clinical study. Notable findings
included significantly faster recovery of renal function
post-transplant, significant reductions in the incidents of acute
rejection and significantly reduced length of hospital stay. Lead
investigators were surgeon-scientists from Sao Paulo based Hospital
do Rim, the world's largest volume renal transplant centre.
Additional studies were presented by surgeon-scientists from Albert
Einstein Hospital (Sao Paulo); General Hospital (Fortaleza), and
the Organ Procurement Organization for the state of Porto
Alegre.
Commenting David Kravitz, CEO of Lifeline Scientific, said: "We
are grateful to see continued further adoption and use of LifePort
within our core North American market. As we highlighted in our
Half Yearly Report, Brazil has the potential to become a
significant market for Lifeline given that it is the world's second
largest national renal transplant market with reportedly over 4,500
deceased donor kidneys recovered annually for transplants across
127 renal transplant centers. These orders, coming on the back of
significant new clinical evidence from Brazil, are an important
milestone for potential wider LifePort adoption as the standard of
care for machine preservation of donor kidneys across the
country."
For further information:
Lifeline Scientific, Inc www.lifeline-scientific.com
David Kravitz, CEO Tel: +1 847 294 0300
Lisa Kieres, CFO Tel: +1 847 294 0300
Panmure Gordon (UK) Ltd Tel: +44 (0)20 7886 2500
Freddy Crossley (Corporate
Finance)
Tom Salvesen (Corporate
Broking)
Walbrook PR Ltd Tel: +44 (0) 20 7933 8780 or lifeline@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Mike Wort Mob: +44 (0)7900 608 002
About Lifeline Scientific, Inc
Lifeline Scientific, is a Chicago-based global medical
technology company with regional offices in Brussels and Sao Paulo.
The Company's focus is the development of innovative products that
improve transplant outcomes and lower the overall costs of
transplantation. Its lead product, LifePort Kidney Transporter, is
the global market-leading medical device for hypothermic machine
preservation of donor kidneys. LifePorts and novel solutions
designed for preservation of other organs are in development, with
LifePort Liver Transporter next in line for commercial launch. For
more information please visit www.lifeline-scientific.com
About LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in
mind, LifePort Kidney Transporter is a proprietary medical device
designed to help improve kidney preservation, evaluation and
transport prior to transplantation. It has been widely studied in
clinical trials throughout the world and is the standard of care
for machine preservation of kidneys. Employed by surgeons in over
206 leading transplant programmes in 29 countries, LifePorts have
preserved more than 70,000 kidneys indicated for clinical
transplant. For more information please visit
www.organ-recovery.com
About LifePort Liver Transporter
LifePort Liver Transporter is modelled upon the clinically
proven technology platform of LifePort Kidney Transporter and the
Company's early HMP prototype successfully used in clinical
transplant studies by surgeons at New York-Presbyterian
Hospital/Columbia University Medical Center. LifePort Liver
Transporter and the Company's proprietary machine preservation
solution, Vasosol(R), are in the process of US and European
regulatory registrations. The system is designed to help improve
outcomes in liver transplantation by enabling the clinical use of
hypothermic machine preservation, and has been developed in
consultation with clinical and research teams specializing in liver
transplantation at Columbia University Medical Center and the
University of Chicago. The system employs a rugged, streamlined
ergonomic design for ease of use and transportability from donor
bedside to recipient operating room. For more information please
visit: http://www.organ-recovery.com/pipeline.php
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCZMMGZFNGGKZZ
(END) Dow Jones Newswires
December 08, 2015 02:00 ET (07:00 GMT)
Lifeline Sci (LSE:LSIC)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Lifeline Sci (LSE:LSIC)
Historical Stock Chart
Von Mai 2023 bis Mai 2024